The EAGLE-1 phase III trial demonstrated that gepotidacin has the potential to be a novel oral treatment option for uncomplicated gonorrhoea. This new medication could offer an effective and convenient alternative for patients with this sexually transmitted infection. The study results suggest that gepotidacin may be a promising solution to combat the rising rates of antibiotic-resistant gonorrhoea. Further research and clinical trials are needed to confirm the efficacy and safety of gepotidacin before it can be widely recommended as a treatment option for this common infection.
Source link
EAGLE-1 phase III trial shows
